IMP [NOT RATED] - ETC channel to drive 2024 revenue; new IMP5 factory in 2027 - Visit Note
  • 23 Jul 2024
  • Company Research
- Imexpharm Pharmaceutical JSC (HOSE: IMP) is the largest antibiotic provider in Vietnam. - IMP reported record-high results in 2023 with net revenue of VND2tn (+21% YoY) and NPAT-MI of VND300bn (+34% YoY). - IMP’s sales from the ETC (essential therapeuti